Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers

Area of Science:

• Pharmacogenetics
• Population Genetics
• Genomics

Background:

• Genetic variations in drug-metabolizing enzymes and transporters influence drug response.
• Understanding pharmacogenetic diversity is crucial for personalized medicine.
• Specific gene polymorphisms (CYP2C9, VKORC1, CYP2C19, ABCB1, CYP2D6, SLCO1B1) are important for drug efficacy and safety.

Purpose of the Study:

• To investigate the prevalence of key gene polymorphisms in Russian ethnic groups.
• To compare allele frequencies of pharmacogenetic markers between Volga (Chuvash, Mari) and Northern Caucasus (Kabardins, Ossetians) populations.

Main Methods:

• Genotyping of 6 key genes (CYP2C9, VKORC1, CYP2C19, ABCB1, CYP2D6, SLCO1B1) was performed.
• Study included 845 healthy volunteers from four distinct ethnic groups in the Russian Federation.
• Allele frequencies were analyzed and compared across the studied populations.

Main Results:

• Significant differences in allele frequencies were observed for CYP2C9, VKORC1, CYP2C19, ABCB1, CYP2D6, and SLCO1B1 polymorphisms.
• These variations were noted between Chuvash and Kabardins, Chuvash and Ossetians, Mari and Kabardians, and Mari and Ossetians.
• The findings indicate distinct pharmacogenetic profiles among these Russian ethnic groups.

Conclusions:

• The study reveals significant ethnic-specific variations in the frequencies of important pharmacogenetic markers.
• These genetic differences have implications for drug metabolism and response in different populations.
• Results underscore the need for population-specific pharmacogenetic data to guide personalized pharmacotherapy.